# Efficacy and tolerability of EPs® 7630 in patients with chronic obstructive pulmonary disease (COPD)

Submission date Recruitment status Prospectively registered 26/03/2009 No longer recruiting [ ] Protocol Statistical analysis plan Registration date Overall study status 14/05/2009 Completed [X] Results [ ] Individual participant data Last Edited Condition category 02/10/2013 Respiratory

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Dina A. Pliskevich

#### Contact details

Faculty Therapy No. 2 National Medical University 4 A, Podvisotskogo str. Kiev Ukraine 01103

# Additional identifiers

# Protocol serial number

701006.01.001

# Study information

#### Scientific Title

Phase III study to prove the efficacy and tolerability of EPs® 7630 in patients aged greater than or equal to 18 years old with chronic obstructive pulmonary disease (COPD)

#### Study objectives

To determine the effect of EPs® 7630 (a liquid herbal drug preparation from the roots of Pelargonium sidoides) on time to occurrence of the first acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) compared to placebo.

# Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics Committee and the State Pharmacological Centre of Ukraine approved on the 26/10/2005 (ref: 5.12-408/KE)

#### Study design

Phase III multicentre double-blind randomised placebo-controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

#### **Interventions**

EPs® 7630 solution or placebo 30 drops three times a day orally for 24 weeks as an add-on therapy to a standardised baseline treatment for COPD.

#### Intervention Type

Drug

#### **Phase**

Phase III

# Drug/device/biological/vaccine name(s)

EPs® 7630 (Pelargonium sidoides extract)

#### Primary outcome(s)

Time to occurrence of first acute exacerbation during the treatment period of 24 weeks.

#### Key secondary outcome(s))

- 1. Number of acute exacerbations during the treatment period of 24 weeks
- 2. Duration of an acute exacerbation until it has subsided
- 3. Measurement of FEV1, forced vital capacity (FVC), and FEV1/FVC ratio every 4 weeks for 24 weeks
- 4. Measurement of FEV1, FVC, and FEV1/FVC ratio at begin and end of an acute exacerbation
- 5. Health status of the patients using the health-related Quality of Life questionnaire (EQ-5D) and St. George's Respiratory Questionnaire (SGRQ), assessed at baseline and every 4 weeks for 24 weeks
- 6. Treatment outcome using the Integrative Medicine Outcomes Scale (IMOS), assessed every 4

weeks for 24 weeks

- 7. Patient's satisfaction with treatment using the Integrative Medicine Patient Satisfaction Scale (IMPSS), assessed every 4 weeks for 24 weeks
- 8. Duration of limitation of physical activity during an acute exacerbation
- 9. Duration of patient's inability to work during an acute exacerbation
- 10. Consumption of paracetamol, Zedex, salmeterol, Berodual N, and budesonide by inhalation during the treatment period of 24 weeks
- 11. Consumption of salmeterol, budesonide, oral prednisone, Berodual N, and augmentinum (or ofloxacin) during an acute exacerbation
- 12. Pack year calculation and changes of smoking habits, assessed at baseline and every 4 weeks for 24 weeks
- 13. Adverse events surveillance: total duration of follow-up: 24 weeks
- 14. Laboratory values, assessed at baseline and every 4 weeks for 24 weeks

#### Completion date

16/06/2008

# **Eligibility**

## Key inclusion criteria

- 1. Aged greater than or equal to 18 years, both males and females
- 2. Written informed consent
- 3. History of chronic bronchitis (characterised by cough and sputum production on most days for a minimum of 3 months per year for at least 2 consecutive years)
- 4. Patients with stable COPD (no changes in volume or appearance of sputum or level of dyspnoea in the previous 4 weeks)
- 5. History of acute exacerbation greater than or equal to 3 times in the prior 12 months
- 6. Forced expiratory volume during one second (FEV1) less than 80% and greater than or equal to 30% predicted (COPD stage II, III)
- 7. Improvement of FEV1 during the initial FEV1 reversibility test is less than or equal to 0.3 l after two puffs of Berodual N  $\,$

## Participant type(s)

Patient

# Healthy volunteers allowed

No

## Age group

Adult

#### Lower age limit

18 years

#### Sex

All

## Key exclusion criteria

1. Patients suffering from cardiac diseases, pneumonia, active pulmonary tuberculosis, cystic fibrosis, bronchiectasis, lung cancer, acquired immune deficiency sydrome (AIDS)

- 2. Patients with asthma bronchiale
- 3. COPD patients in stage IV (FEV1 less than 30% predicted)
- 4. Patients with infiltrates or other abnormalities of the lungs indicating an active pathological process on chest x-ray
- 5. Patients with acute exacerbation within the last 4 weeks
- 6. Known concomitant bacterial infection or infections of respiratory tract
- 7. Concomitant medication with beta-blockers, angiotensin converting enzyme (ACE)-inhibitors, regular inhalative glucocorticoids (except in COPD patients stage III), oral glucocorticoids (except during an acute exacerbation), anticholinergics (except ipratropium bromide in Berodual N), beta-2-agonists other than salmeterol or fenoterol in Berodual N, analgetics other than paracetamol, mucolytics and antitussives other than Zedex, immunomodulators (e.g. bacterial vaccines), or coumarin-derivatives
- 8. Treatment with antibiotics, beta-blockers, ACE-inhibitors, anticholinergics (except ipratropium bromide in Berodual N), inhalative glucocorticoids (except in COPD patients stage III) or oral glucocorticoids within the last 4 weeks prior study inclusion
- 9. Known alcohol or drug abuse
- 10. Patients with tendency to bleed
- 11. Severe heart, renal or liver diseases and/or immunosuppression
- 12. Gastrointestinal disorders
- 13. Patients with known or supposed hypersensitivity against EPs® 7630
- 14. Females of child-bearing potential with no adequate contraception
- 15. Pregnancy or lactation
- 16. Patients participating in another clinical trial at the same time or have taken part in a clinical trial during the last 3 months before inclusion into this study
- 17. Irresponsible patients or those unable to understand nature, meaning and consequences of the trial

Date of first enrolment 13/03/2006

Date of final enrolment 16/06/2008

# Locations

**Countries of recruitment**Ukraine

Study participating centre Faculty Therapy No. 2 Kiev Ukraine 01103

# Sponsor information

# Organisation

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

#### **ROR**

https://ror.org/043rrkc78

# Funder(s)

# Funder type

Industry

#### Funder Name

Dr Willmar Schwabe GmbH & Co. KG (Germany)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2013		Yes	No